| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20045027 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20049925 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20025509 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS20049443 | HPV | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
| TVIS44014966 | HTLV-1 | ENSG00000149295.14 | protein_coding | DRD2 | No | No | 1813 | P14416 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DRD2 |
|---|---|
| DrugBank ID | DB01238 |
| Drug Name | Aripiprazole |
| Target ID | BE0000756 |
| UniProt ID | P14416 |
| Regulation Type | antagonist |
| PubMed IDs | 16366516; 9083792; 16925992; 16981227; 17501690; 11752352; 26346901; 16554049 |
| Citations | Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90.@@Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11.@@Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21.@@Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28.@@Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.@@Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A: Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol. 2006 Mar 27;535(1-3):135-44. doi: 10.1016/j.ejphar.2006.01.051. Epub 2006 Mar 22. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpiperazines |
| SMILES | ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl |
| Pathways | |
| PharmGKB | PA10026 |
| ChEMBL | CHEMBL1112 |
